{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T03:24:48Z","timestamp":1791170688928,"version":"4.1.0"},"reference-count":114,"publisher":"Wiley","issue":"S3","license":[{"start":{"date-parts":[[2008,1,1]],"date-time":"2008-01-01T00:00:00Z","timestamp":1199145600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2008,9,9]],"date-time":"2008-09-09T00:00:00Z","timestamp":1220918400000},"content-version":"vor","delay-in-days":252,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mov. Disord."],"published-print":{"date-parts":[[2008]]},"DOI":"10.1002\/mds.22028","type":"journal-article","created":{"date-parts":[[2008,9,13]],"date-time":"2008-09-13T05:03:49Z","timestamp":1221282229000},"page":"S497-S508","source":"Crossref","is-referenced-by-count":298,"special_numbering":"supplement S3","title":["The history of dopamine and levodopa in the treatment of Parkinson's disease"],"prefix":"10.1002","volume":"23","author":[{"given":"Stanley","family":"Fahn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,9,9]]},"reference":[{"key":"10.1002\/mds.22028-BIB1|cit1","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1056\/NEJM196702162760703","article-title":"Aromatic amino acids and modification of parkinsonism","volume":"276","author":"Cotzias","year":"1967","journal-title":"N Engl J Med"},{"key":"10.1002\/mds.22028-BIB2|cit2","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1056\/NEJM196902132800701","article-title":"Modification of parkinsonism-chronic treatment with L-DOPA","volume":"280","author":"Cotzias","year":"1969","journal-title":"N Engl J Med"},{"key":"10.1002\/mds.22028-BIB3|cit3","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0079-6123(08)63411-1","article-title":"The contribution of basal ganglia to limb control","volume":"64","author":"DeLong","year":"1986","journal-title":"Prog Brain Res"},{"key":"10.1002\/mds.22028-BIB4|cit4","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/mds.870010102","article-title":"Striatal inhomogeneities and basal ganglia function","volume":"1","author":"Penney","year":"1986","journal-title":"Mov Disord"},{"key":"10.1002\/mds.22028-BIB5|cit5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0306-4522(87)90322-8","article-title":"Primate models of dyskinesia: the experimental approach to the study of basal ganglia-related involuntary movement disorders","volume":"21","author":"Crossman","year":"1987","journal-title":"Neuroscience"},{"key":"10.1002\/mds.22028-BIB6|cit6","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1002\/mds.10115","article-title":"Dopamine miracle: from brain homogenate to dopamine replacement","volume":"17","author":"Hornykiewicz","year":"2002","journal-title":"Mov Disord"},{"key":"10.1002\/mds.22028-BIB7|cit7","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s00726-001-0111-9","article-title":"L-DOPA: from a biologically inactive amino acid to a successful therapeutic agent","volume":"23","author":"Hornykiewicz","year":"2002","journal-title":"Amino Acids"},{"key":"10.1002\/mds.22028-BIB8|cit8","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1113\/jphysiol.1910.sp001392","article-title":"Chemical structure and sympathomimetic action of amines","volume":"41","author":"Barger","year":"1910","journal-title":"J Physiol"},{"key":"10.1002\/mds.22028-BIB9|cit9","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1039\/CT9119900554","article-title":"Synthesis of dl-3:4-dihydroxyphenylalanine","volume":"99","author":"Funk","year":"1911","journal-title":"J Chem Soc"},{"key":"10.1002\/mds.22028-BIB10|cit10","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1515\/bchm2.1913.88.4.276","article-title":"Dioxyphenylalanin, eine neue Aminos\u00e4ure aus Vicia faba","volume":"88","author":"Guggenheim","year":"1913","journal-title":"Hoppe-Seyler's Zeitschr Physiol Chem"},{"key":"10.1002\/mds.22028-BIB11|cit11","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/BF01994628","article-title":"Fermentativer Abbau von Ldioxyphenylalanin (Dopa) durch Niere","volume":"191","author":"Holtz","year":"1938","journal-title":"Naunyn-Schmiedeberg's Arch Exp Path Pharmak"},{"key":"10.1002\/mds.22028-BIB12|cit12","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1007\/BF01494245","article-title":"Dopadecarboxylase","volume":"27","author":"Holtz","year":"1939","journal-title":"Naturwissenschaften"},{"key":"10.1002\/mds.22028-BIB13|cit13","first-page":"50","article-title":"The specific action of L-DOPA decarboxylase","volume":"96","author":"Blaschko","year":"1939","journal-title":"J Physiol"},{"key":"10.1002\/mds.22028-BIB14|cit14","first-page":"133","article-title":"[On the effect of dopamine on the blood pressure.]","volume":"246","author":"Holtz","year":"1963","journal-title":"Naunyn Schmiedebergs Arch Exp Pathol Pharmakol"},{"key":"10.1002\/mds.22028-BIB15|cit15","first-page":"91","article-title":"The action of dopamine on the arterial pressure of the guinea pig","volume":"13","author":"Hornykiewicz","year":"1958","journal-title":"Brit J Pharmacol"},{"key":"10.1002\/mds.22028-BIB16|cit16","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1016\/S0021-9258(18)93832-9","article-title":"Tyrosine hydroxylase: the initial step in norepinephrine biosynthesis","volume":"239","author":"Nagatsu","year":"1964","journal-title":"J Biol Chem"},{"key":"10.1002\/mds.22028-BIB17|cit17","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1515\/BC.1999.175","article-title":"Molecular genetics of dopa-responsive dystonia","volume":"380","author":"Ichinose","year":"1999","journal-title":"Biol Chem"},{"key":"10.1002\/mds.22028-BIB18|cit18","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/ng1293-386","article-title":"Linkage mapping of dopa-responsive dystonia (DRD) to chromosome 14q","volume":"5","author":"Nygaard","year":"1993","journal-title":"Nat Genet"},{"key":"10.1002\/mds.22028-BIB19|cit19","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1126\/science.122.3165.374","article-title":"Serotonin release as a possible mechanism of reserpine action","volume":"122","author":"Pletscher","year":"1955","journal-title":"Science"},{"key":"10.1002\/mds.22028-BIB20|cit20","first-page":"107","volume-title":"Biochemistry and pharmacology of the basal ganglia","author":"Carlsson","year":"1966"},{"key":"10.1002\/mds.22028-BIB21|cit21","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/1801200a0","article-title":"3,4-Dihydroxyphenylalanine and 5-hydroxytroptophan as reserpine antagonists","volume":"180","author":"Carlsson","year":"1957","journal-title":"Nature"},{"key":"10.1002\/mds.22028-BIB22|cit22","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/BF02189076","article-title":"\u00dcber die Wirkungen des L-dopa beim Menschen und deren Beeinflussung durch Reserpin, Chlorpromazin, Iproniazid und Vitamin B6","volume":"38","author":"Degkwitz","year":"1960","journal-title":"Klin Wochenschr"},{"key":"10.1002\/mds.22028-BIB23|cit23","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/180244a0","article-title":"Catechol compounds in rat tissues and in brains of different animals","volume":"180","author":"Montagu","year":"1957","journal-title":"Nature"},{"key":"10.1002\/mds.22028-BIB24|cit24","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1038\/1801050a0","article-title":"Intracellular distribution of catecholamines in the brain","volume":"180","author":"Weil-Malherbe","year":"1957","journal-title":"Nat Lond"},{"key":"10.1002\/mds.22028-BIB25|cit25","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3181\/00379727-76-18398","article-title":"Concentration and distribution of \u201cencephalin\u201d in the brain of humans and animals","volume":"76","author":"Raab","year":"1951","journal-title":"Proc Soc Exp Biol Med"},{"key":"10.1002\/mds.22028-BIB26|cit26","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1126\/science.127.3296.471","article-title":"On the presence of 3-hydroxytyramine in the brain","volume":"127","author":"Carlsson","year":"1958","journal-title":"Science"},{"key":"10.1002\/mds.22028-BIB27|cit27","first-page":"350","article-title":"Occurrence and distribution of catechol amines in brain","volume":"47","author":"Bertler","year":"1959","journal-title":"Acta Physiol Scand"},{"key":"10.1002\/mds.22028-BIB28|cit28","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/0006-3002(59)90652-3","article-title":"Distribution of catechol compounds in human brain","volume":"32","author":"Sano","year":"1959","journal-title":"Biochim Biophys Acta"},{"issue":"2, Part 2","key":"10.1002\/mds.22028-BIB29|cit29","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/S0031-6997(25)07428-9","article-title":"The occurrence, distribution and physiological role of catecholamines in the nervous system","volume":"11","author":"Carlsson","year":"1959","journal-title":"Pharmacol Rev"},{"key":"10.1002\/mds.22028-BIB30|cit30","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1007\/BF01485901","article-title":"Verteilung von Noradrenalin und Dopamin (3-Hydroxytyramin) im Gehirn des Mensachen und ihr Verhalten bei Erkrankungen des extrapyramidalen Systems","volume":"38","author":"Ehringer","year":"1960","journal-title":"Klin Wochenschr"},{"key":"10.1002\/mds.22028-BIB31|cit31","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S0031-6997(25)07154-6","article-title":"Dopamine (3-hydroxytyramine) and brain function","volume":"18","author":"Hornykiewicz","year":"1966","journal-title":"Pharmacol Rev"},{"key":"10.1002\/mds.22028-BIB32|cit32","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/0024-3205(64)90161-4","article-title":"Demonstration and mapping out of nigro-neostriatal dopamine neurons","volume":"3","author":"Anden","year":"1964","journal-title":"Life Sci"},{"key":"10.1002\/mds.22028-BIB33|cit33","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1093\/brain\/88.1.181","article-title":"Influence of the substantia nigra on the catecholamine content of the striatum","volume":"88","author":"Poirier","year":"1965","journal-title":"Brain"},{"key":"10.1002\/mds.22028-BIB34|cit34","doi-asserted-by":"crossref","first-page":"11869","DOI":"10.1073\/pnas.97.22.11869","article-title":"Neuromelanin biosynthesis is driven by excess cytosolic catecholamines not accumulated by synaptic vesicles","volume":"97","author":"Sulzer","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1002\/mds.22028-BIB35|cit35","first-page":"787","article-title":"Der L-3,4-Dioxyphenylalanin (DOPA)-Effekt bei der Parkinson-Akinese","volume":"73","author":"Birkmayer","year":"1961","journal-title":"Wien Klin Wochenschr"},{"key":"10.1002\/mds.22028-BIB36|cit36","first-page":"247","volume-title":"Symposium sur les monoamines et systeme nerveux central","author":"Barbeau","year":"1962"},{"key":"10.1002\/mds.22028-BIB37|cit37","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1001\/jama.1963.73700170010010c","article-title":"Dihydroxyphenylalanine in extrapyramidal disease","volume":"184","author":"Friedhoff","year":"1964","journal-title":"JAMA"},{"key":"10.1002\/mds.22028-BIB38|cit38","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/BF00395715","article-title":"Die Wirksamkeit von L-Dopa bei Parkinson-Patienten mit und ohne sterotaktischen Herneingriff","volume":"205","author":"Umbach","year":"1964","journal-title":"Arch Psychiat Nervenkr"},{"key":"10.1002\/mds.22028-BIB39|cit39","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1055\/s-0028-1113210","article-title":"Zur Beeinflussung von L-Dopa (L-Dihydroxyphenylananin)","volume":"89","author":"Hirschmann","year":"1964","journal-title":"Deutsch Med Wschr"},{"key":"10.1002\/mds.22028-BIB40|cit40","first-page":"138","article-title":"La Sperimentazione clinica del Dopa nelle sindromi parkinsoniane","volume":"12","author":"Fazzagli","year":"1966","journal-title":"Riv Neurobiol"},{"key":"10.1002\/mds.22028-BIB41|cit41","first-page":"39","article-title":"Effetti dell L-2,4-dihydossifenilalanina (L-Dopa) nei pazienti parkinsoniani","volume":"90","author":"Bruno","year":"1966","journal-title":"Riv Sper Freniatr"},{"key":"10.1002\/mds.22028-BIB42|cit42","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1212\/WNL.13.1.73","article-title":"Dopamine metabolism in Parkinson's disease","volume":"13","author":"Greer","year":"1963","journal-title":"Neurology"},{"key":"10.1002\/mds.22028-BIB43|cit43","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1055\/s-0028-1103669","article-title":"Was leistet L-DOPA bei der Behandlung der Parkinson-Akinese?","volume":"92","author":"Aebert","year":"1967","journal-title":"Deutsch Med Wschr"},{"key":"10.1002\/mds.22028-BIB44|cit44","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/j.1600-0404.1966.tb01188.x","article-title":"Treatment of Parkinson's syndrome with L-DOPA, a double-blind study","volume":"42","author":"Fehling","year":"1966","journal-title":"Acta Neurol Scand"},{"issue":"Suppl 1","key":"10.1002\/mds.22028-BIB45|cit45","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2165\/00003495-199855001-00004","article-title":"Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group","volume":"55","author":"Rinne","year":"1998","journal-title":"Drugs"},{"key":"10.1002\/mds.22028-BIB46|cit46","first-page":"463","article-title":"Administration of dihyroxyphenylalanine to parkinsonian patients","volume":"90","author":"McGeer","year":"1964","journal-title":"Canad Med Assoc J"},{"issue":"Suppl 1","key":"10.1002\/mds.22028-BIB47|cit47","first-page":"55","article-title":"Autopsy findings in parkinsonism following treatment with levodopa","volume":"6","author":"Yahr","year":"1970","journal-title":"Neurology"},{"key":"10.1002\/mds.22028-BIB48|cit48","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1001\/archneur.1969.00480160015001","article-title":"Treatment of parkinsonism with levodopa","volume":"21","author":"Yahr","year":"1969","journal-title":"Arch Neurol"},{"key":"10.1002\/mds.22028-BIB49|cit49","doi-asserted-by":"crossref","first-page":"29","DOI":"10.7326\/0003-4819-72-1-29","article-title":"Treatment of Parkinson's syndrome with dihydroxyphenylalanine (levodopa)","volume":"72","author":"McDowell","year":"1970","journal-title":"Ann Int Med"},{"key":"10.1002\/mds.22028-BIB50|cit50","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/S0025-7125(16)32643-8","article-title":"Newer medical treatments in parkinsonism","volume":"54","author":"Schwarz","year":"1970","journal-title":"Med Clin North Am"},{"key":"10.1002\/mds.22028-BIB51|cit51","first-page":"21","article-title":"Problems with L-DOPA therapy","volume":"78","author":"Calne","year":"1971","journal-title":"Clin Med"},{"key":"10.1002\/mds.22028-BIB52|cit52","first-page":"203","volume-title":"Current concepts in the treatment of parkinsonism","author":"Duvoisin","year":"1974"},{"key":"10.1002\/mds.22028-BIB53|cit53","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1001\/archneur.1975.00490470075011","article-title":"Levodopa-induced myoclonus","volume":"32","author":"Klawans","year":"1975","journal-title":"Arch Neurol"},{"key":"10.1002\/mds.22028-BIB54|cit54","first-page":"331","article-title":"The \u201con-off\u201d response to chronic L-DOPA treatment of parkinsonism","volume":"5","author":"Sweet","year":"1974","journal-title":"Adv Neurol"},{"key":"10.1002\/mds.22028-BIB55|cit55","first-page":"397","article-title":"Variations in the \u201con-off\u201d effect","volume":"5","author":"Yahr","year":"1974","journal-title":"Adv Neurol"},{"key":"10.1002\/mds.22028-BIB56|cit56","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1212\/WNL.24.5.431","article-title":"\u201cOn-off\u201d phenomenon with levodopa therapy in parkinsonism: clinical and pharmacologic correlations and the effect of intramuscular pyridoxine","volume":"24","author":"Fahn","year":"1974","journal-title":"Neurology"},{"key":"10.1002\/mds.22028-BIB57|cit57","first-page":"72","volume-title":"Neurological reviews 1976","author":"Fahn","year":"1976"},{"key":"10.1002\/mds.22028-BIB58|cit58","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/S0140-6736(76)91416-1","article-title":"\u201cOn-off\u201d effects in patients with Parkinson's disease on chronic levodopa therapy","volume":"1","author":"Marsden","year":"1976","journal-title":"Lancet"},{"key":"10.1002\/mds.22028-BIB59|cit59","first-page":"163","article-title":"Patterns of dystonia (\u201cI-D-I\u201d and \u201cD-I-D\u201d) in response to L-DOPA therapy of Parkinson's disease","volume":"52","author":"Muenter","year":"1977","journal-title":"Mayo Clin Proc"},{"key":"10.1002\/mds.22028-BIB60|cit60","first-page":"96","volume-title":"Movement disorders","author":"Marsden","year":"1982"},{"key":"10.1002\/mds.22028-BIB61|cit61","first-page":"123","volume-title":"Movement disorders","author":"Fahn","year":"1982"},{"key":"10.1002\/mds.22028-BIB62|cit62","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/S0140-6736(77)92939-7","article-title":"\u201cOff period\u201d dystonia and \u201con period\u201d choreoathetosis in levodopa-treated patients with Parkinson's disease","volume":"2","author":"Lees","year":"1977","journal-title":"Lancet"},{"key":"10.1002\/mds.22028-BIB63|cit63","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1001\/archneur.1979.00500410086014","article-title":"Early-morning dystonia: a late side effect of long-term levodopa therapy in Parkinson's disease","volume":"36","author":"Melamed","year":"1979","journal-title":"Arch Neurol"},{"key":"10.1002\/mds.22028-BIB64|cit64","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1212\/WNL.36.1.100","article-title":"Episodic unresponsiveness to single doses of L-Dopa in parkinsonian fluctuators","volume":"36","author":"Melamed","year":"1986","journal-title":"Neurology"},{"key":"10.1002\/mds.22028-BIB65|cit65","first-page":"55","article-title":"Modification of L-DOPA therapy of Parkinsonism by alpha-methyldopa hydrazine (MK-486)","volume":"96","author":"Yahr","year":"1971","journal-title":"Trans Am Neurol Assoc"},{"key":"10.1002\/mds.22028-BIB66|cit66","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1056\/NEJM197201062860102","article-title":"Levodopa in Parkinsonism: potentiation of central effects with a peripheral inhibitor","volume":"286","author":"Papavasiliou","year":"1972","journal-title":"N Engl J Med"},{"issue":"Suppl","key":"10.1002\/mds.22028-BIB67|cit67","first-page":"169","article-title":"Treatment of Parkinson's disease with L-DOPA alone or combined with Ro 4-4602","volume":"31","author":"Barbeau","year":"1972","journal-title":"Rev Can Biol"},{"key":"10.1002\/mds.22028-BIB68|cit68","first-page":"167","article-title":"MK 486 and levodopa in treatment of Parkinsonism","volume":"34","author":"Lieberman","year":"1973","journal-title":"Dis Nerv Syst"},{"key":"10.1002\/mds.22028-BIB69|cit69","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S0140-6736(73)90586-2","article-title":"Methyldopa or methyldopahydrazine as levodopa synergists","volume":"1","author":"Fermaglich","year":"1973","journal-title":"Lancet"},{"key":"10.1002\/mds.22028-BIB70|cit70","first-page":"340","article-title":"2-year experiences with a combination treatment of Parkinsonism with L-DOPA and a decarboxylase inhibitor (Benserazid, Ro 4-4602)","volume":"124","author":"Birkmayer","year":"1974","journal-title":"Wien Med Wochenschr"},{"key":"10.1002\/mds.22028-BIB71|cit71","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1001\/archneur.1974.00490380076010","article-title":"Carbidopa in Parkinson disease and in nausea and vomiting of levodopa","volume":"31","author":"Markham","year":"1974","journal-title":"Arch Neurol"},{"key":"10.1002\/mds.22028-BIB72|cit72","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1001\/archneur.1975.00490500080010","article-title":"Treatment of \u201con-off effect\u201d with a dopa decarboxylase inhibitor","volume":"32","author":"Sweet","year":"1975","journal-title":"Arch Neurol"},{"key":"10.1002\/mds.22028-BIB73|cit73","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1136\/bmj.311.7020.1602","article-title":"Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease","volume":"311","author":"Lees","year":"1995","journal-title":"Br Med J"},{"key":"10.1002\/mds.22028-BIB74|cit74","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/ana.10191","article-title":"Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial","volume":"51","author":"Shoulson","year":"2002","journal-title":"Ann Neurol"},{"key":"10.1002\/mds.22028-BIB75|cit75","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1159\/000407513","article-title":"(\u2212)-Deprenyl leads to prolongation of L-DOPA efficacy in Parkinson's disease","volume":"19","author":"Birkmayer","year":"1983","journal-title":"Mod Probl Pharmacopsychiatry"},{"key":"10.1002\/mds.22028-BIB76|cit76","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/j.1600-0404.1983.tb01524.x","article-title":"Clinical and pharmacological problems of deprenyl (selegiline) treatment in Parkinson's disease","volume":"95","author":"Stern","year":"1983","journal-title":"Acta Neurol Scand Suppl"},{"key":"10.1002\/mds.22028-BIB77|cit77","first-page":"13","article-title":"Deprenyl in the treatment of Parkinson's disease. A specific type B monoamine oxidase inhibitor","volume":"84","author":"Lieberman","year":"1984","journal-title":"N Y State J Med"},{"key":"10.1002\/mds.22028-BIB78|cit78","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/00002826-198802000-00004","article-title":"Deprenyl in the treatment of symptom fluctuations in advanced Parkinson's disease","volume":"11","author":"Golbe","year":"1988","journal-title":"Clin Neuropharmacol"},{"key":"10.1002\/mds.22028-BIB79|cit79","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1001\/archneur.62.2.241","article-title":"A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations-The PRESTO study","volume":"62","author":"Parkinson Study Group","year":"2005","journal-title":"Arch Neurol"},{"key":"10.1002\/mds.22028-BIB80|cit80","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/S0140-6736(05)71083-7","article-title":"Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomized, double-blind, parallel-group trial","volume":"365","author":"Rascol","year":"2005","journal-title":"Lancet"},{"key":"10.1002\/mds.22028-BIB81|cit81","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/BF01245973","article-title":"Increased life expectancy resulting from addition of L-deprenyl to Madopar treatment in Parkinson's disease: a long-term study","volume":"64","author":"Birkmayer","year":"1985","journal-title":"J Neural Transm"},{"key":"10.1002\/mds.22028-BIB82|cit82","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1056\/NEJM199301213280305","article-title":"Effects of tocopherol and deprenyl on the progression of disability in early parkinson's disease","volume":"328","author":"Parkinson Study Group","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1002\/mds.22028-BIB83|cit83","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1212\/01.wnl.0000204007.46190.54","article-title":"Selegiline slows the progression of the symptoms of Parkinson disease","volume":"66","author":"Palhagen","year":"2006","journal-title":"Neurology"},{"key":"10.1002\/mds.22028-BIB84|cit84","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1001\/archneur.61.4.561","article-title":"A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease","volume":"61","author":"Parkinson Study Group","year":"2004","journal-title":"Arch Neurol"},{"key":"10.1002\/mds.22028-BIB85|cit85","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1212\/WNL.43.12.2685","article-title":"Catechol-O-methyltransferase inhibitor tolcapone prolongs levodopa\/carbidopa action in parkinsonian patients","volume":"43","author":"Roberts","year":"1993","journal-title":"Neurology"},{"key":"10.1002\/mds.22028-BIB86|cit86","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1016\/0140-6736(93)90750-B","article-title":"Ro 40-7592, a COMT inhibitor, plus levodopa in Parkinson's disease","volume":"341","author":"Limousin","year":"1993","journal-title":"Lancet"},{"key":"10.1002\/mds.22028-BIB87|cit87","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/mds.870100321","article-title":"Effects of tolcapone in Parkinson's patients taking L-dihydroxyphenylalanine\/carbidopa and selegiline","volume":"10","author":"Davis","year":"1995","journal-title":"Mov Disord"},{"key":"10.1002\/mds.22028-BIB88|cit88","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1212\/WNL.48.1.81","article-title":"Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: a multicenter, double-blind, randomized, placebo-controlled trial. Tolcapone Fluctuator Study Group I","volume":"48","author":"Kurth","year":"1997","journal-title":"Neurology"},{"key":"10.1002\/mds.22028-BIB89|cit89","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1212\/WNL.44.1.77","article-title":"Effect of entacapone, a COMT inhibitor, on clinical disability and levodopa metabolism in parkinsonian patients","volume":"44","author":"Kaakkola","year":"1994","journal-title":"Neurology"},{"key":"10.1002\/mds.22028-BIB90|cit90","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1136\/jnnp.57.2.186","article-title":"Effect of entacapone, a peripherally acting catechol-o-methyltransferase inhibitor, on the motor response to acute treatment with levodopa in patients with Parkinson's disease","volume":"57","author":"Merello","year":"1994","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1002\/mds.22028-BIB91|cit91","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1136\/jnnp.60.1.36","article-title":"Entacapone prolongs levodopa response in a one month double blind study in parkinsonian patients with levodopa related fluctuations","volume":"60","author":"Ruottinen","year":"1996","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1002\/mds.22028-BIB92|cit92","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/00002826-199619040-00001","article-title":"A double-blind pharmacokinetic and clinical dose-response study of entacapone as an adjuvant to levodopa therapy in advanced Parkinson's disease","volume":"19","author":"Ruottinen","year":"1996","journal-title":"Clin Neuropharmacol"},{"key":"10.1002\/mds.22028-BIB93|cit93","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/S1474-4422(06)70521-X","article-title":"Continuous dopamine receptor stimulation in the treatment of parkinson's disease: scientific rationale and clinical implications","volume":"5","author":"Olanow","year":"2006","journal-title":"Lancet Neurol"},{"key":"10.1002\/mds.22028-BIB94|cit94","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/00002826-198406000-00003","article-title":"Controlled-release carbidopa\/levodopa in the treatment of parkinsonism","volume":"7","author":"Hutton","year":"1984","journal-title":"Clin Neuropharmacol"},{"key":"10.1002\/mds.22028-BIB95|cit95","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1212\/WNL.36.9.1206","article-title":"Clinical and biochemical studies with controlled-release levodopa\/carbidopa","volume":"36","author":"Nutt","year":"1986","journal-title":"Neurology"},{"key":"10.1002\/mds.22028-BIB96|cit96","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1136\/jnnp.50.2.194","article-title":"Controlled release levodopa treatment of motor fluctuations in Parkinson's disease","volume":"50","author":"Juncos","year":"1987","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1002\/mds.22028-BIB97|cit97","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1212\/WNL.37.2.233","article-title":"Controlled-release levodopa\/carbidopa. I. Sinemet CR3 treatment of response fluctuations in Parkinson's disease","volume":"37","author":"Cedarbaum","year":"1987","journal-title":"Neurology"},{"key":"10.1002\/mds.22028-BIB98|cit98","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1212\/WNL.37.5.875","article-title":"Parkinson's disease and motor fluctuations: long-acting carbidopa\/levodopa (CR-4-Sinemet)","volume":"37","author":"Goetz","year":"1987","journal-title":"Neurology"},{"key":"10.1002\/mds.22028-BIB99|cit99","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1001\/archneur.1987.00520220016008","article-title":"Controlled release levodopa-carbidopa (CR-5) in the management of parkinsonian motor fluctuations","volume":"44","author":"Juncos","year":"1987","journal-title":"Arch Neurol"},{"key":"10.1002\/mds.22028-BIB100|cit100","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1097\/00002826-198804000-00008","article-title":"Controlled-release levodopa\/carbidopa. III: sinemet CR5 treatment of response fluctuations in Parkinson's disease","volume":"11","author":"Cedarbaum","year":"1988","journal-title":"Clin Neuropharmacol"},{"key":"10.1002\/mds.22028-BIB101|cit101","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1097\/00002826-198804000-00009","article-title":"Comparison of controlled-release Sinemet (CR4) and standard Sinemet (25 mg\/100 mg) in advanced Parkinson's disease: a double-blind, crossover study","volume":"11","author":"Sage","year":"1988","journal-title":"Clin Neuropharmacol"},{"key":"10.1002\/mds.22028-BIB102|cit102","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1212\/WNL.38.7.1143","article-title":"Controlled-release carbidopa\/levodopa (CR4-Sinemet) in Parkinson's disease patients with and without motor fluctuations","volume":"38","author":"Goetz","year":"1988","journal-title":"Neurology"},{"issue":"Suppl 2","key":"10.1002\/mds.22028-BIB103|cit103","first-page":"67","article-title":"Multicenter controlled study of Sinemet CR vs Sinemet (25\/100) in advanced Parkinson's disease","volume":"39","author":"Hutton","year":"1989","journal-title":"Neurology"},{"issue":"Suppl 1","key":"10.1002\/mds.22028-BIB104|cit104","first-page":"51","article-title":"Long-acting carbidopa-levodopa in the management of moderate and advanced Parkinson's disease","volume":"42","author":"Hutton","year":"1992","journal-title":"Neurology"},{"key":"10.1002\/mds.22028-BIB105|cit105","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1097\/00002826-198610000-00003","article-title":"Treatment of motor fluctuations in Parkinson's disease with an oral sustained-release preparation of L-DOPA: clinical and pharmacokinetic observations","volume":"9","author":"Poewe","year":"1986","journal-title":"Clin Neuropharmacol"},{"issue":"Suppl 1","key":"10.1002\/mds.22028-BIB106|cit106","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1159\/000116204","article-title":"Open study of Madopar HBS, a new formulation of levodopa with benserazide, in 13 patients with Parkinson's disease and \u201con-off\u201d fluctuations","volume":"27","author":"Quinn","year":"1987","journal-title":"Eur Neurol"},{"issue":"Suppl 1","key":"10.1002\/mds.22028-BIB107|cit107","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1159\/000116205","article-title":"Clinical trial of Madopar HBS in parkinsonian patients with fluctuating drug response after long-term levodopa therapy","volume":"27","author":"Rondot","year":"1987","journal-title":"Eur Neurol"},{"issue":"Suppl 1","key":"10.1002\/mds.22028-BIB108|cit108","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1159\/000116206","article-title":"Madopar HBS in the long-term treatment of parkinsonian patients with fluctuations in disability","volume":"27","author":"Rinne","year":"1987","journal-title":"Eur Neurol"},{"issue":"Suppl 1","key":"10.1002\/mds.22028-BIB109|cit109","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1159\/000116207","article-title":"A sustained-release formulation of L-DOPA (Madopar HBS) in the treatment of nocturnal and early-morning disabilities in Parkinson's disease","volume":"27","author":"Lees","year":"1987","journal-title":"Eur Neurol"},{"key":"10.1002\/mds.22028-BIB110|cit110","first-page":"171","volume-title":"Biochemistry and pharmacology of the basal ganglia","author":"Hornykiewicz","year":"1966"},{"key":"10.1002\/mds.22028-BIB111|cit111","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1212\/WNL.28.1.5","article-title":"Considerations in the management of parkinsonism","volume":"28","author":"Fahn","year":"1978","journal-title":"Neurology"},{"key":"10.1002\/mds.22028-BIB112|cit112","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1212\/WNL.31.2.125","article-title":"Evidence to support early levodopa therapy in Parkinson disease","volume":"31","author":"Markham","year":"1981","journal-title":"Neurology"},{"key":"10.1002\/mds.22028-BIB113|cit113","first-page":"119","article-title":"Monoamine oxidase, hydrogen peroxide, and Parkinson's disease","volume":"45","author":"Cohen","year":"1986","journal-title":"Adv Neurol"},{"key":"10.1002\/mds.22028-BIB114|cit114","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1056\/NEJMoa033447","article-title":"Levodopa and the progression of PD","volume":"351","author":"Fahn","year":"2004","journal-title":"New Engl J Med"}],"container-title":["Movement Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmds.22028","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmds.22028","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/mds.22028\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T22:50:41Z","timestamp":1738363841000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/mds.22028"}},"subtitle":["Dopamine and Levodopa in the Treatment of PD"],"short-title":[],"issued":{"date-parts":[[2008]]},"references-count":114,"journal-issue":{"issue":"S3","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1002\/mds.22028","archive":["Portico"],"relation":{},"ISSN":["0885-3185"],"issn-type":[{"value":"0885-3185","type":"print"}],"subject":[],"published":{"date-parts":[[2008]]}}}